First Seizure Evaluation

The evaluation of a patient presenting with a first seizure is one of the most common and consequential clinical scenarios in neurology. The initial assessment must accomplish several goals simultaneously: determine whether the event was an epileptic seizure, distinguish provoked (acute symptomatic) from unprovoked seizures, identify immediate threats requiring emergent intervention, estimate the risk of seizure recurrence, and guide the decision of whether to initiate long-term antiseizure medication. A systematic approach that integrates clinical history, targeted laboratory testing, EEG, and neuroimaging forms the foundation for accurate diagnosis and appropriate management.

Bottom Line

Acute symptomatic (provoked) seizures occur within 7 days of an acute brain insult or systemic disturbance and generally do not require long-term antiseizure medication
After a single unprovoked seizure, the overall recurrence risk is approximately 40–50% within 2 years; however, this risk rises to ≥60% when an epileptiform EEG abnormality, structural brain lesion, or nocturnal seizure is present
EEG is the single most useful ancillary test in the evaluation of a first seizure — epileptiform discharges are found in approximately 20–50% of patients with a first unprovoked seizure on initial routine EEG
MRI with epilepsy protocol is the preferred neuroimaging modality; CT is appropriate emergently but insufficient for definitive evaluation
Treatment after a first seizure reduces recurrence risk by approximately 35% but does not alter the long-term prognosis of epilepsy; the decision to treat should be individualized
The differential diagnosis includes syncope (most common mimic), psychogenic nonepileptic seizures, parasomnias, movement disorders, and migraine — misdiagnosis of epilepsy occurs in up to 20–25% of cases
Driving restrictions vary by jurisdiction but most US states require a seizure-free interval of 3–12 months (commonly 6 months)

Acute Symptomatic vs. Unprovoked Seizures

The critical first distinction in first seizure evaluation is whether the seizure was acute symptomatic (provoked) or unprovoked, as this fundamentally changes management and prognosis.

Feature	Acute Symptomatic (Provoked)	Unprovoked
Definition	Seizure occurring within 7 days of an acute brain insult or systemic disturbance	Seizure occurring in the absence of an identifiable acute trigger or >7 days after a brain insult
Common causes	Alcohol withdrawal, metabolic derangements (hyponatremia, hypoglycemia, uremia), acute stroke, CNS infection, traumatic brain injury, drug toxicity	Remote structural lesion, idiopathic/genetic factors, remote CNS infection, unknown cause
Recurrence risk	3–10% over 10 years (if provoked factor is corrected)	40–50% over 2 years (overall); ≥60% with EEG abnormality or structural lesion
Long-term ASM	Generally not indicated; treat the underlying cause	Consider based on recurrence risk; mandatory if meets epilepsy definition
Diagnosis of epilepsy?	No — provoked seizures do not count toward epilepsy diagnosis	One unprovoked seizure + ≥60% recurrence risk = epilepsy diagnosis per ILAE

An important exception applies to infectious and parasitic diseases, where acute symptomatic seizures can persist beyond the conventional 7-day window due to persistent brain inflammation. Notably, in patients with viral encephalitis, the presence of acute symptomatic seizures increases the likelihood of developing epilepsy by 22-fold.

Red Flags Requiring Emergent Evaluation

Persistent altered mental status that does not improve within 30–60 minutes post-seizure — consider ongoing nonconvulsive status epilepticus, structural pathology, or metabolic emergency
Focal neurologic deficits beyond transient Todd paralysis — may indicate acute stroke, intracranial hemorrhage, or mass lesion
Fever with seizure in adults — raises concern for CNS infection (meningitis, encephalitis); lumbar puncture may be warranted
History of cancer — new seizure may be the first presentation of brain metastasis or leptomeningeal disease
Immunocompromised patient — broader infectious differential including toxoplasmosis, progressive multifocal leukoencephalopathy, CMV encephalitis
Anticoagulation or coagulopathy — risk of intracranial hemorrhage as the precipitant
Pregnancy — consider eclampsia, posterior reversible encephalopathy syndrome (PRES), or cerebral venous thrombosis
Seizure in the setting of recent head trauma — urgent neuroimaging required to exclude epidural or subdural hematoma

Clinical Assessment

The clinical history is the most important element in first seizure evaluation. Since the patient is often amnestic to the event, witness descriptions are invaluable and should be actively sought. The assessment should systematically address:

Pre-Ictal History

Triggers and circumstances — sleep deprivation, alcohol use or withdrawal, drug use, missed medications, illness, metabolic disturbance, photic stimulation
Warning signs (aura) — any subjective experience immediately before the event; character of the aura has localizing value
Activity at onset — was the patient awake or asleep? Standing, sitting, or supine? Exerting themselves?
Positional context — events occurring during prolonged standing or in hot environments raise suspicion for syncope

Ictal Description

Onset pattern — was there focal onset (head turning, unilateral jerking, aura) before bilateral involvement?
Motor features — tonic stiffening, clonic jerking, automatisms, hyperkinetic movements; bilateral or unilateral?
Duration — most epileptic seizures last 1–3 minutes; events lasting >5 minutes raise concern for status epilepticus; very prolonged events (>10–15 minutes) raise suspicion for nonepileptic episodes
Awareness — was the patient responsive during the event?
Incontinence — occurs in both seizures and syncope; not specific for either
Tongue bite — lateral tongue bite has high specificity for generalized tonic-clonic seizures; tip-of-tongue bite is nonspecific

Post-Ictal Findings

Confusion — postictal confusion lasting minutes is characteristic of seizure; immediate return to baseline raises suspicion for syncope
Focal deficits — Todd paralysis (postictal focal weakness), postictal aphasia
Somatic injury — posterior shoulder dislocation, vertebral compression fractures, oral lacerations
Muscle soreness — generalized myalgias from tonic-clonic activity

Relevant Medical History

Certain risk factors predispose to epilepsy and should be specifically queried:

History of febrile seizures (especially complex febrile seizures)
Prior traumatic brain injury
Prior meningitis or encephalitis
Cerebrovascular disease (stroke, vascular malformations)
Family history of epilepsy
History of brain tumors or neurosurgery
Neurodevelopmental disorders
Prior similar episodes that may have gone unrecognized (eg, absence seizures, myoclonic jerks, nocturnal events)

Clinical Pearl: Uncovering Prior Seizures

Carefully reviewing the history of a patient presenting with a “first seizure” may reveal prior similar episodes that were not recognized as seizures
Ask specifically about: brief staring episodes (absence seizures), morning myoclonic jerks (JME), nocturnal events (frontal lobe seizures), déjà vu episodes with impaired awareness (temporal lobe seizures)
When evaluating a 17-year-old with a new-onset GTC seizure, prior staring episodes suggestive of absence seizures or myoclonic jerking could provide supportive evidence for underlying idiopathic generalized epilepsy
Discuss with family members or caregivers — patients often do not disclose or recognize these events as abnormal

Diagnostic Workup

Laboratory Testing

Initial laboratory evaluation serves primarily to identify provoked (acute symptomatic) seizures that require correction of the underlying cause rather than long-term antiseizure medication.

Test	Purpose	Key Thresholds / Notes
Complete blood count	Infection screening; baseline before starting ASMs	Leukocytosis may suggest infection or postictal stress response
Basic metabolic panel	Electrolyte abnormalities (Na, Ca, Mg, glucose)	Sodium <120 mEq/L, glucose <40 mg/dL, calcium <7 mg/dL — common provoked seizure thresholds
Blood glucose	Hypoglycemia or hyperglycemia	Hypoglycemia is a common and reversible cause of seizures
Serum calcium / magnesium	Hypocalcemia, hypomagnesemia	Low magnesium may also lower seizure threshold
Hepatic / renal function	Uremia, hepatic encephalopathy	Relevant for ASM dosing if treatment initiated
Toxicology screen	Drug intoxication or withdrawal	Cocaine, amphetamines, synthetic cannabinoids; alcohol level
Serum prolactin	Elevated 10–20 minutes post-seizure (GTC or focal impaired awareness)	Sensitivity is limited; primarily useful to distinguish epileptic GTC from PNES; must be drawn within 20 minutes
Lumbar puncture	If CNS infection or autoimmune encephalitis is suspected	Fever, immunocompromised status, meningismus, or persistent altered mental status

Electroencephalography (EEG)

EEG is the single most useful ancillary test in first seizure evaluation. It serves three primary purposes: (1) supporting the diagnosis that the event was an epileptic seizure, (2) classifying the seizure and epilepsy type (focal vs. generalized), and (3) identifying a specific epilepsy syndrome when possible.

Timing matters: EEG yield is highest when performed within 24–48 hours of the seizure; the sensitivity of a routine EEG for detecting epileptiform discharges after a first seizure is approximately 20–50%
Sleep recording increases yield: Sleep deprivation and recording during sleep increases the detection of epileptiform discharges, as many patterns are activated during drowsiness and sleep
Normal EEG does not exclude epilepsy: Epilepsy is a clinical diagnosis — an EEG showing epileptiform discharges is not required for establishing the diagnosis if the clinical presentation is convincing
Prolonged or ambulatory EEG: If the routine EEG is non-diagnostic but clinical suspicion remains high, prolonged or ambulatory EEG monitoring (24–72 hours) increases the diagnostic yield
Epileptiform discharges after a first seizure significantly increase the recurrence risk and may be sufficient to diagnose epilepsy after a single unprovoked seizure (when recurrence risk exceeds 60%)

Clinical Pearl: EEG Interpretation Caveats

EEG is a supportive test, not a definitive diagnostic test — if there is strong clinical suspicion of an epileptic seizure, the diagnosis can be made irrespective of EEG results
Epileptiform discharges can occur in 0.5–2% of the general population without epilepsy — they must be interpreted in clinical context
Conversely, up to 50% of patients with epilepsy may have a normal initial routine EEG
Certain normal variants (wicket spikes, benign epileptiform transients of sleep, small sharp spikes) are commonly misread as epileptiform and lead to misdiagnosis
If a specific epilepsy syndrome is suspected (eg, JME), EEG should include hyperventilation and photic stimulation to maximize sensitivity

Neuroimaging

Neuroimaging is recommended for all patients with spontaneous (unprovoked) seizures, particularly if they exhibit focal electroclinical features. The goals are to identify structural etiologies (stroke, tumor, mesial temporal sclerosis, cortical dysplasia, vascular malformations) and guide prognosis and management.

Modality	Strengths	Limitations	When to Use
Non-contrast CT	Rapid; widely available; detects hemorrhage, calcified lesions, large mass lesions, skull defects	Poor sensitivity for subtle structural abnormalities (cortical dysplasia, hippocampal sclerosis, small tumors)	Emergency setting; first-time seizure workup; when MRI is contraindicated or unavailable
MRI with epilepsy protocol	Superior sensitivity for hippocampal sclerosis, cortical dysplasia, low-grade tumors, vascular malformations, subtle structural abnormalities	Longer acquisition time; less available in resource-limited settings; may require sedation	All patients with suspected focal epilepsy; definitive imaging for all first seizure evaluations when possible; minimum 1.5 Tesla recommended

In certain clinical scenarios, neuroimaging may not be necessary — particularly in children presenting with specific clinical and EEG patterns such as those with typical idiopathic generalized epilepsy syndromes. However, because the majority of spontaneous seizures in adults are focal, imaging should be considered for all adult patients with a first seizure.

Risk of Recurrence After First Seizure

Understanding the risk of seizure recurrence is central to the decision of whether to initiate antiseizure medication after a first unprovoked seizure.

Risk Factor	Impact on Recurrence Risk	Estimated Risk
No identified risk factors	Baseline risk	~40–50% over 2 years
Epileptiform EEG abnormality	Substantially increases risk; may exceed 60% threshold for epilepsy diagnosis	~60–70% over 2 years
Structural brain lesion (prior stroke, TBI, tumor)	Substantially increases risk; concordant with seizure semiology = high risk	~60–70% over 2 years
Nocturnal seizure (during sleep)	Increases risk compared to daytime seizure	Higher than baseline
Prior brain insult >7 days before seizure	Remote symptomatic seizure; increased recurrence risk	~50–65% over 2 years
Family history of epilepsy	Modest increase in risk	Modestly above baseline
Abnormal neurologic examination	Suggests underlying structural or neurodevelopmental etiology	Increased above baseline
Two or more risk factors combined	Cumulative increase; often exceeds 60% threshold	≥60% over 2 years

The ILAE practical definition of epilepsy allows diagnosis after a single unprovoked seizure when the estimated recurrence risk is at least 60% over the next 10 years, similar to the recurrence risk after two unprovoked seizures. This threshold is typically met when an epileptiform EEG abnormality, a concordant structural brain lesion, or identification of an epilepsy syndrome is present.

When to Start Treatment After First Seizure

The decision to initiate antiseizure medication (ASM) after a first unprovoked seizure is one of the most important decisions in epilepsy management and should be individualized based on recurrence risk, patient preferences, and risk-benefit analysis.

Evidence from Key Trials

The landmark FIRST (First Seizure Trial) and MESS (Multicentre trial of Early Epilepsy and Single Seizures) trials, synthesized in the AAN/AES guideline, established that:

Immediate treatment after a first seizure produces an absolute reduction in 2-year recurrence risk of about 35% (relative risk roughly halved)
However, immediate treatment does not alter the long-term remission rate at 5 years — patients who defer treatment until a second seizure achieve the same long-term seizure control
This means that early treatment delays the second seizure but does not change whether the patient ultimately achieves seizure freedom

Indications Favoring Immediate Treatment

Recurrence risk ≥60% (meets ILAE definition of epilepsy after a single seizure)
Epileptiform EEG abnormalities
Structural brain lesion concordant with seizure type
Nocturnal seizure with high risk of injury
Patient occupation or activities where seizure recurrence poses significant safety risk (eg, commercial driving, working at heights)
Patient preference after understanding risks and benefits
Identification of an epilepsy syndrome (eg, JME presenting with a first GTC but with preceding myoclonic jerks)

Situations Favoring Deferral of Treatment

Low recurrence risk (normal EEG, normal MRI, no risk factors)
Acute symptomatic seizure with correctable cause
Patient preference to observe after informed discussion
Concerns about medication side effects (teratogenicity in women of childbearing potential, cognitive effects, drug interactions)
Uncertainty about whether the event was truly an epileptic seizure

Clinical Pearl: Shared Decision-Making

The decision to treat or defer after a first seizure should involve a thorough discussion with the patient about recurrence risk, driving implications, safety risks, and medication side effects
Present the evidence clearly: treatment reduces recurrence risk in the short term but does not change the long-term outcome
For patients who defer treatment, establish a clear plan for follow-up and for what to do if a second seizure occurs
Document the discussion and the patient’s informed decision in the medical record

Driving Restrictions After First Seizure

Driving restrictions after a first seizure are governed by state or jurisdictional regulations and are an important practical consideration for patients. Key points include:

Most US states require a seizure-free interval of 3 to 12 months before driving privileges are restored; the most common requirement is 6 months
Commercial driving (CDL holders) typically has more stringent requirements, often requiring longer seizure-free intervals and, in some jurisdictions, freedom from antiseizure medications
Physician reporting varies by state — some states have mandatory reporting laws, while others rely on patient self-reporting
Provoked seizures may have different driving implications than unprovoked seizures in some jurisdictions, particularly if the provoking factor has been corrected
Clinicians should document the driving restriction discussion and refer patients to their state’s Department of Motor Vehicles for specific regulations

Differential Diagnosis

Misdiagnosis of epilepsy occurs in approximately 20–25% of cases. A careful differential diagnosis is essential before committing a patient to a lifetime diagnosis of epilepsy and long-term medication use.

Condition	Key Distinguishing Features	Diagnostic Approach
Syncope (convulsive syncope)	Provoked by prolonged standing, pain, or Valsalva; brief myoclonic jerks possible during syncope; rapid return to baseline (<1 min); pallor at onset; no lateral tongue bite; no postictal confusion beyond brief seconds	Tilt-table testing; cardiac evaluation (ECG, Holter); witness history distinguishes from epileptic seizure
Psychogenic nonepileptic seizures (PNES)	Variable semiology between events; prolonged duration (>5 min); waxing/waning pattern; eyes typically closed; preserved pupillary reflexes; resistance to passive eye opening; pelvic thrusting (can also occur in frontal seizures); no postictal confusion	Video-EEG monitoring (gold standard); normal ictal EEG during typical event; serum prolactin normal
Transient ischemic attack (TIA)	Sudden onset of focal neurologic symptoms (weakness, speech difficulty, visual loss) that resolve within 24 hours, usually within 30–60 minutes; typically negative symptoms (loss of function) rather than positive symptoms (jerking, tingling)	Vascular imaging (CT angiography, MR angiography); diffusion-weighted MRI; cardiac evaluation
Migraine with aura	Visual aura evolves slowly over 5–60 minutes (vs. seconds for seizure); typically followed by headache; zigzag/fortification spectra rather than colored circles; no impaired awareness or motor convulsion	Clinical history; ICHD-3 criteria; seizures and migraine can coexist (migralepsy is rare)
Parasomnias	Complex behaviors during sleep (sleepwalking, sleep terrors, REM behavior disorder); variable semiology; typically arise from specific sleep stages; no epileptiform discharges on EEG	Polysomnography with video; sleep-related hypermotor epilepsy can closely mimic parasomnias and requires video-EEG for differentiation
Movement disorders	Paroxysmal dyskinesias (paroxysmal kinesigenic dyskinesia, paroxysmal nonkinesigenic dyskinesia); tics; myoclonus of non-epileptic origin; preserved awareness; stereotyped but triggered by specific stimuli	Clinical history; genetic testing (PRRT2 for PKD); normal EEG
Panic attacks	Intense fear with palpitations, sweating, trembling, dyspnea; builds over minutes (vs. seconds for ictal fear); no impaired awareness; no automatisms or motor convulsion; responsive to anxiolytics	Clinical history; psychiatric evaluation; consider ictal fear if episodes are stereotyped and brief (<2 min)

Pitfalls in First Seizure Diagnosis

Convulsive syncope is often misdiagnosed as epilepsy: Brief myoclonic jerks during syncope (from cerebral hypoperfusion) occur in up to 10–15% of syncope episodes and do not indicate epilepsy; the jerks are typically brief (a few seconds), irregular, and asymmetric
A lateral tongue bite has high specificity for generalized tonic-clonic seizures and is one of the most reliable clinical features distinguishing seizures from syncope; tip-of-tongue bites are nonspecific
Incontinence alone is not diagnostic: Urinary incontinence occurs in both seizures and syncope and should not be used as a sole discriminating factor
Starting ASMs without adequate evaluation: Initiating long-term ASM therapy before a complete workup (including EEG and ideally MRI) can commit a patient to unnecessary treatment — except in situations requiring emergent seizure control
Misinterpretation of EEG: Normal EEG variants misread as epileptiform discharges are a leading cause of epilepsy misdiagnosis; ensure EEG interpretation by qualified neurophysiologists
Failure to consider autoimmune etiologies: In patients with new-onset seizures and encephalopathic features, autoimmune encephalitis (NMDA receptor, LGI1, GAD) should be considered; early immunotherapy is the recommended treatment

Physical Examination Considerations

While the neurologic examination may be normal in many patients presenting with a first seizure, several findings warrant careful attention:

Dysmorphic features — may suggest a genetic syndrome associated with epilepsy (eg, tuberous sclerosis, neurofibromatosis)
Cutaneous manifestations — ash-leaf spots, shagreen patches, or facial angiofibromas suggest tuberous sclerosis; café-au-lait spots suggest neurofibromatosis
Focal neurologic impairments — hemiparesis, visual field deficits, or hemispatial neglect suggest an underlying structural abnormality
Papilledema — raises concern for increased intracranial pressure (mass lesion, venous thrombosis)
Tongue laceration — lateral tongue bite supports the diagnosis of GTC seizure
Todd paralysis — transient postictal focal weakness indicates focal seizure with contralateral hemisphere onset; typically resolves within minutes to hours

Approach to New-Onset Seizures: A Diagnostic Algorithm

Stepwise First Seizure Evaluation

Step 1 — Was this an epileptic seizure? Obtain detailed witness and patient history; distinguish from syncope, PNES, TIA, migraine, parasomnia, and movement disorders
Step 2 — Is this provoked or unprovoked? Review labs, toxicology, and clinical context; identify and correct acute symptomatic causes
Step 3 — Classify the seizure type. Apply the ILAE 2017 framework: focal vs. generalized vs. unknown onset; motor vs. nonmotor; awareness level
Step 4 — Obtain EEG. Ideally within 24–48 hours; include sleep recording; interpret in clinical context
Step 5 — Obtain neuroimaging. CT emergently if indicated; MRI with epilepsy protocol for definitive evaluation of all adults with a first unprovoked seizure
Step 6 — Assess recurrence risk. Integrate EEG findings, imaging results, clinical history, and examination findings to estimate recurrence risk
Step 7 — Determine epilepsy type and syndrome. If sufficient information is available, classify the epilepsy type (focal, generalized, combined, unknown) and identify any specific syndrome
Step 8 — Investigate etiology. Structural, genetic, infectious, metabolic, immune, or unknown; additional testing (genetic, antibodies, metabolic) as indicated
Step 9 — Shared decision-making regarding treatment. Discuss recurrence risk, treatment benefits and risks, driving restrictions, and safety precautions
Step 10 — Safety counseling and follow-up. Driving restrictions, water safety, heights, seizure first aid, SUDEP education (if applicable), and follow-up plan

Special Populations

Elderly Patients

Cerebrovascular disease is the most frequent cause of late-onset epilepsy in adults, with Alzheimer disease and other neurodegenerative disorders also contributing significantly to the development of late-onset epilepsy. In elderly patients with a first seizure:

MRI is particularly important to evaluate for stroke, tumor, and neurodegenerative changes
Subtle focal seizures may present as recurrent confusional episodes or transient cognitive impairment
Drug interactions and side effect profiles are important considerations when selecting ASMs in the elderly
Lower starting doses are generally appropriate due to altered pharmacokinetics

Children

In children, the diagnostic approach differs in several ways:

Febrile seizures are the most common childhood seizure type and are distinct from epilepsy; complex febrile seizures carry a higher risk of subsequent epilepsy
Specific electroclinical syndromes (childhood absence epilepsy, SeLECTS) have characteristic presentations that may not require MRI if the clinical and EEG picture is classic
Inborn metabolic disorders remain important considerations in children presenting with seizures and should prompt early evaluation
Genetic testing may be particularly valuable in children with unexplained epilepsy, especially when developmental concerns are present

References

Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475–482.
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):522–530.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705–1713.
Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1475–1499.
Nascimento FA, Friedman D, Peters JM, et al. Focal epilepsies: update on diagnosis and classification. Epileptic Disord 2023;25(1):1–17.
Yacubian EMT, Kakooza-Mwesige A, Singh G, et al. Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy. Epileptic Disord 2022;24(6):994–1019.
Almannai M, Al Mahmoud RA, Mekki M, El-Hattab AW. Metabolic seizures. Front Neurol 2021;12:640371.
Ricci L, Boscarino M, Assenza G, et al. Clinical utility of home videos for diagnosing epileptic seizures: a systematic review and practical recommendations. Neurol Sci 2021;42(4):1301–1309.
Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood. Epilepsia 2022;63(6):1398–1442.
Sveinsson O, Andersson T, Mattsson P. Clinical risk factors in SUDEP: a nationwide population-based case-control study. Neurology 2020;94(4).
Skidmore CT. Neuroimaging in epilepsy. Continuum (Minneap Minn) 2025;31(1, Epilepsy):61–80.
Fisher RS, Cross JH, D’Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017;58(4):531–542.
Scheffer IE, French J, Hirsch E, et al. Classification of the epilepsies: new concepts for discussion and debate. Epilepsia Open 2016;1(1-2):37–44.
Beniczky S, Tatum WO, Blumenfeld H, et al. Seizure semiology: ILAE glossary of terms and their significance. Epileptic Disord 2022;24(3):447–495.